Abstract

We have shown that both reactive oxygen species (ROS) and paxillin tyrosine phosphorylation regulate LPS-induced human lung endothelial permeability. Mitochondrial ROS (mtROS) is known to increase endothelial cell (EC) permeability which requires dynamic change in mitochondrial morphology, events that are likely to be regulated by paxillin. Here, we investigated the role of paxillin and its tyrosine phosphorylation in regulating LPS-induced mitochondrial dynamics, mtROS production and human lung microvascular EC (HLMVEC) dysfunction. LPS, in a time-dependent manner, induced higher levels of ROS generation in the mitochondria compared to cytoplasm or nucleus. Down-regulation of paxillin expression with siRNA or ecto-expression of paxillin Y31F or Y118F mutant plasmids attenuated LPS-induced mtROS in HLMVECs. Pre-treatment with MitoTEMPO, a scavenger of mtROS, attenuated LPS-induced mtROS, endothelial permeability and VE-cadherin phosphorylation. Further, LPS-induced mitochondrial fission in HLMVECs was attenuated by both a paxillin siRNA, and paxillin Y31F/Y118F mutant. LPS stimulated phosphorylation of dynamin-related protein (DRP1) at S616, which was also attenuated by paxillin siRNA, and paxillinY31/Y118 mutants. Inhibition of DRP1 phosphorylation by P110 attenuated LPS-induced mtROS and endothelial permeability. LPS challenge of HLMVECs enhanced interaction between paxillin, ERK, and DRP1, and inhibition of ERK1/2 activation with PD98059 blocked mitochondrial fission. Taken together, these results suggest a key role for paxillin tyrosine phosphorylation in LPS-induced mitochondrial fission, mtROS generation and EC barrier dysfunction.

Details

Title
Essential role for paxillin tyrosine phosphorylation in LPS-induced mitochondrial fission, ROS generation and lung endothelial barrier loss
Author
Fu Panfeng 1 ; Epshtein Yulia 2 ; Ramchandran Ramaswamy 3 ; Mascarenhas, Joseph B 4 ; Cress, Anne E 5 ; Jacobson, Jeffrey 2 ; Garcia Joe G N 4 ; Viswanathan, Natarajan 6 

 University of Illinois at Chicago, Department of Pharmacology, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319); Medical School of Ningbo University, The Affiliated Hospital of Medical School, Ningbo, China (GRID:grid.203507.3) (ISNI:0000 0000 8950 5267) 
 University of Illinois at Chicago, Department of Medicine, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319) 
 University of Illinois at Chicago, Department of Pharmacology, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319) 
 University of Arizona Health Sciences, Department of Medicine, College of Medicine, Tucson, USA (GRID:grid.134563.6) (ISNI:0000 0001 2168 186X) 
 University of Arizona Health Sciences, Departments of Cellular and Molecular Medicine, Tucson, USA (GRID:grid.134563.6) (ISNI:0000 0001 2168 186X); University of Arizona Health Sciences, Department of Medicine, College of Medicine, Tucson, USA (GRID:grid.134563.6) (ISNI:0000 0001 2168 186X) 
 University of Illinois at Chicago, Department of Pharmacology, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319); University of Illinois at Chicago, Department of Medicine, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2568394333
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.